ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag fda pharma tuberculosis industry

Concerns over Efficacy and Cost of Muscle Wasting Treatments
Ruth Williams | Nov 11, 2020 | 5 min read
Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.
Single Nucleotide Polymorphisms: Big Pharma Hedges its Bets
Eugene Russo | Jul 18, 1999 | 7 min read
SNP CENTRAL: A genetics researcher takes to the bench at the Wellcome Trust's Sanger Centre in Cambridge, England. The sequencing center and its London sponsor provided key leadership in the SNP Consortium, a public-private venture to find and map 300,000 single nucleotide polymorphisms. The Wellcome Trust helped entice 10 pharmaceutical firms to join the consortium by putting up $14 million of the project's estimated $45 million price tag. The Sanger Centre will provide much of the radiation h
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Antidepressant Approvals Could Herald New Era in Psychiatric Drugs
Bianca Nogrady | Oct 1, 2019 | 9 min read
The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.
Nice Shot
Megan Scudellari | Jan 1, 2010 | 10+ min read
By Megan Scudellari Nice Shot Why vaccines are pharma’s Next Big Thing. ILLUSTRATION BY Jason Raish Late at night, a feverish young girl shuffled into her father’s room complaining of a sore throat. Maurice Hilleman examined the swollen bumps on his daughter’s neck. It was 1963. She had the mumps, a common childhood disease at the time, caused by a virus that inflames the salivary glands. Most cases are mild, but severe inf
Updated July 9
Track COVID-19 Vaccines Advancing Through Clinical Trials
The Scientist | Apr 7, 2020 | 10+ min read
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.
Getting Your Gates
Juhi Yajnik | Nov 1, 2006 | 6 min read
How one company used the growing nonprofit funding pot to jump-start its development program, and how you can do the same.
Fighting the 10/90 Gap
Ricki Lewis | May 12, 2002 | 5 min read
While wealthy nations pursue drugs to treat baldness and obesity, depression in dogs, and erectile dysfunction, elsewhere millions are sick or dying from preventable or treatable infectious and parasitic diseases.1 It's called the 10/90 gap. "Less than 10% of the worldwide expenditure on health research and development is devoted to the major health problems of 90% of the population," explains Els Torreele, co-chair of a working group that provided background recently for an initiative announced
Mining the Ubiquitin Pathway
John Hall(hall@lifesensors.com) | Dec 4, 2005 | 5 min read
In October 2004, the Royal Swedish Academy of Sciences awarded the Nobel Prize in Chemistry to Aaron Ciechanover, Avram Hersko, and Irwin Rose "for the discovery of ubiquitin-mediated protein degradation."
Venture Capital, with a Twist
Ted Agres(tagres@the-scientist.com) | Jul 17, 2005 | 5 min read
Jamie Heywood, chief executive of the Amyotrophic Lateral Sclerosis Therapy Development Foundation (ALSTDF), founded the nonprofit biotech company in 1999 after his brother was diagnosed with ALS.

Run a Search

ADVERTISEMENT